Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia

Annals of Clinical Psychiatry

Volumn 15, Issue 3-4, 2003, Pages 181-186

  Kelly, Deanna L ^a,b   Conley, Robert R ^a   Richardson, Charles M ^a   Tamminga, Carol A ^a   Carpenter Jr , William T ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Clozapine; Olanzapine; Schizophrenia; Side effects; Treatment resistant

Indexed keywords

CLOZAPINE; LIPID; LIVER ENZYME; OLANZAPINE;

ADULT; AKATHISIA; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPEPSIA; DYSPHAGIA; ENZYME BLOOD LEVEL; FEMALE; HEADACHE; HUMAN; HYPERSALIVATION; INCREASED APPETITE; LABORATORY TEST; LETHARGY; LIPID BLOOD LEVEL; MALE; MYOCLONUS; NAUSEA; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STUTTERING; SWEATING; TACHYCARDIA; URINARY FREQUENCY; URINARY HESITANCY; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHRONIC DISEASE; CLOZAPINE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN;

EID: 0842327252     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:ACLI.0000008171.90644.f8     Document Type: Article

References (21)

1. Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123
2. Tollefson G, Beasley C, Tran P, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorder: Results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
3. Conley RR, Kelly DL: Management of treatment-resistant schizophrenia. Biol. Psychiatry 2001; 50:898-911
4. Love RC: Novel versus conventional antipsychotic drugs. Pharmacotherapy 1996; 16:6-10
5. Conley RR, Tamminga CA, Richardson CM, Kelly DL: Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol. Psychiatry 1999; 46: 73-77
6. Sheitman B, Lindgren J, Early J, Sved M: High-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 1997; 154:1626
7. Alao A, Armenta WA, Yolles JC: High-dose olanzapine therapy in schizophrenia. Ann Pharmacother 1999; 33:1228
8. Reich J: Use of high-dose olanzapine in refractory psychosis. Am J Psychiatry 1999; 156:661
9. Fanous A, Lindenmyer JP: Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. J Clin Psychopharmacol 1999; 3:275-276
10. Mountjoy CQ, Baldacchino AM, Stubbs JH: British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 1999; 156:158-159
11. Dursun SM, Gardner DM, Bird DC, Flinn J: Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study. Can J Psychiatry 1999; 44:701-704
12. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Liberman JA: Clozapine, olanzapine, risperidone and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 59:255-262
13. Bronson BD, Lindenmayer J-P. Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. J Clin Psychopharmacol 2000; 20:382-384
14. Citrome L, Volavka J: Optimal dosing of atypical antipsychotics in adults: A review of the current evidence. Harv Rev Psychiatry 2002; 10:280-291
15. DeRenzo EG, Conley RR, Love RC: Assessment of Capacity to give consent to research participation: State-of-the-art and beyond. J Health Care Law Policy 1998; 1(1):66-87
16. Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT, Jr: The efficacy of high dose olanzapine vs. clozapine in treatment-resistant schizophrenia: A double-blind crossover study. J Clin Psychopharmacol (in press).
17. Gerlach J: Improving outcome in schizophrenia: The potential importance of eps and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14:47-57
18. Kelly DL, Conley RR, Tamminga CA: Differential olanzapine plasma concentrations by sex in a fixed dose study. Schizophr Res 1999; 40(2): 101-104
19. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ: Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001; 49:52-63
20. Tracy JI, Monaco C, Giovannetti T, Abraham G, Josiassen RC: Anticholinergicity and cognitive processing in chronic schizophrenia. Biol Psychiatry 2001; 56:1-22
21. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25:233-255